The latest headlines across every section, pulled from official and open-access sources.
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
Parents urged to immediately stop using all Nara Organics Whole Milk Organic Infant Formula.
Nara Organics of New York, NY, is voluntarily recalling all lots of Nara Organics Powdered Infant Formula currently on the market out of an abundance of caution due to the potential risk of Clostridium botulinum contamination. Infant botulism is a rare but potentially fatal illness that presents a s
Industrial action by resident doctors will be taking place from 7am on Monday 15 June to 6:59am Friday 19 June 2026. This four-day strike coincides with more expected hot weather and the start of the football World Cup, with millions turning out to watch England’s first match against Croatia on Wednesday. The NHS’s top doctor […]
An OIG report found that the three largest Medicare Advantage insurers denied prior authorization requests for long-term acute care and inpatient rehabilitation at higher rates than other MA plans in 2024. The post OIG: 3 Largest MA Insurers Deny Prior Auth Requests at High Rates for Long-Term Acute Care, Inpatient Rehab appeared first on MedCity News .
FDA concerns about Amgen’s Tavneos were sparked by securities fraud litigation against ChemoCentryx, the company that originally developed the rare disease drug. The FDA wants to withdraw Tavneos’s approval, citing safety risks and alleged manipulation of the drug’s clinical trial data. The post Amgen Defends Rare Disease Drug in FDA Crosshairs appeared first on MedCity News .
Dr Nicola Rose, Executive Director of Science and Research at the Medicines and Healthcare products Regulatory Agency (MHRA), has been appointed an OBE in the 2026 King’s Birthday Honours, for services to science and public health.
Recipients of the King's Ambulance Service Medal 2026.
This technical specifications document represents the Food and Drug Administration's (FDA's) current thinking on this topic.
The healthcare industry is spending more than ever on AI — but according to executives from Oracle Health, HCA Healthcare and BJC Health, much of that investment could be wasted. During a panel this week at HFMA’s annual conference, they argued that no amount of sophisticated tech can overcome a broken, antiquated data foundation. The post Bot vs. Bot: Why Healthcare AI Progress Might Be Stuck appeared first on MedCity News .
News about human drug-related approvals
The U.S. Food and Drug Administration (FDA) has approved Tzield (teplizumab) injection to delay (slow down) the loss of the body’s own insulin production for pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 Type I diabetes (T1D).
The ADA Acknowledges Continued Federal Funding for Diabetes Research and Prevention vcramer Fri, 06/12/2026 - 19:43 Official Statement The ADA Acknowledges Continued Federal Funding for Diabetes Research and Prevention Arlington, Va. June 15, 2026 The American Diabetes Association® (ADA) issued the following statement in response to the House Appropriations Committee’s passage of the Fiscal Year (FY) 2027 funding bill for the Department of Health and Human Services (HHS). This week, the House Appropriations Committee passed a FY 2027 funding measure that…
The U.S. Food and Drug Administration today cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM) for children, Dexcom Inc.’s Stelo Glucose Biosensor System, an integrated CGM (iCGM) indicated for people two years of age and older who do not use insulin.
CDC Activates Emergency Operations Center for New World Screwworm Response
On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive p
Estimating the risk for nonlive birth, abnormal fetal growth, and major congenital malformation (MCM) with GLP-1RA dispensing in early pregnancy.
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
This workshop is designed to facilitate discussions about the latest advancements and regulatory considerations in the evolving field of patient-centric (including pediatric) generic oral products, addressing product development and regulatory assessment challenges for these important medicines.
The Office of Health Technology and Products is the latest technology development from the CMS as it doubles down on digital tools.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell
January - March 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
July - September 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)